161 related articles for article (PubMed ID: 31576678)
1. TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining.
Shi D; Liu W; Zhao S; Zhang C; Liang T; Hou G
J Cell Mol Med; 2019 Dec; 23(12):8305-8313. PubMed ID: 31576678
[TBL] [Abstract][Full Text] [Related]
2. TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.
Shi D; Zhao S; Jiang W; Zhang C; Liang T; Hou G
Cell Death Dis; 2019 Dec; 10(12):954. PubMed ID: 31852883
[TBL] [Abstract][Full Text] [Related]
3. Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging.
Jiang W; Han Y; Liang T; Zhang C; Gao F; Hou G
Front Oncol; 2021; 11():708047. PubMed ID: 34336694
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb.
Sun H; Yang G; Liang T; Zhang C; Song J; Han J; Hou G
J Cell Mol Med; 2014 Dec; 18(12):2437-44. PubMed ID: 25283154
[TBL] [Abstract][Full Text] [Related]
5. In vivo Toll-like receptor 5 (TLR5) imaging with radiolabeled anti-TLR5 monoclonal antibody in rapamycin-treated mouse allogeneic skin transplantation model.
Sun H; Zhan Y; Liang T; Zhang C; Song J; Han J; Hou G
Transpl Infect Dis; 2015 Feb; 17(1):80-8. PubMed ID: 25573439
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive imaging of Toll-like receptor 5 expression using
Yang C; Yun Q; Sun H; Yang G; Liang T; Zhang C; Song J; Han J; Hou G
Oncol Lett; 2014 Jun; 7(6):1919-1924. PubMed ID: 24932259
[TBL] [Abstract][Full Text] [Related]
7. CC chemokine receptor 7 promotes triple-negative breast cancer growth and metastasis.
Wu J; Li L; Liu J; Wang Y; Wang Z; Wang Y; Liu W; Zhou Z; Chen C; Liu R; Yang R
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):835-842. PubMed ID: 30032244
[TBL] [Abstract][Full Text] [Related]
8. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
[TBL] [Abstract][Full Text] [Related]
9. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
[TBL] [Abstract][Full Text] [Related]
10.
Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
12. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
15. SMAR1 promotes immune escape of Tri-negative Breast Cancer through a mechanism involving T-bet/PD-1 Axis.
Xiaohua W; Hongxia X; Rong D; Pingping W; Xing H; Yichao Z; Cheng C
Cell Mol Biol (Noisy-le-grand); 2018 Sep; 64(12):70-75. PubMed ID: 30301506
[TBL] [Abstract][Full Text] [Related]
16. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression.
Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Deladriere C; Palomino-Schätzlein M; Lamas-Domingo R; Forteza J; Pineda-Lucena A; Vicent MJ
Int J Cancer; 2019 Oct; 145(8):2267-2281. PubMed ID: 30860605
[TBL] [Abstract][Full Text] [Related]
17. Study on biodistribution and radioimmunoimaging of (131)iodine-labeled monoclonal antibody D-D3 against progastrin-releasing peptide31-98 in tumor-bearing mouse.
Liu Z; Zhou X; Shi Y; Du S; Yang Y; Tang J; Shen Y
Cancer Biother Radiopharm; 2011 Apr; 26(2):229-35. PubMed ID: 21510749
[TBL] [Abstract][Full Text] [Related]
18. Invasion and Metastasis Suppression by Anti-Neonatal Nav1.5 Antibodies in Breast Cancer.
Sharudin NA; Murtadha Noor Din AH; Azahar II; Mohd Azlan M; Yaacob NS; Sarmiento ME; Dominguez AA; Mokhtar NF
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2953-2964. PubMed ID: 36172657
[TBL] [Abstract][Full Text] [Related]
19. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
